PE 22-28 is a spadin-derived heptapeptide studied for rapid antidepressant effects through TREK‑1 channel blockade, and users commonly report it for mood improvement and as a fast‑acting antidepressant in research settings. Community reports show uniformly positive mood effects, with all six mood‑balance submissions reporting improvement. Community protocols typically involve a daily dose of 10 mg, the most frequently cited amount, with reported ranges from 150 µg up to 10 mg, while timing and cycling are rarely specified. The primary limitation is that it has no FDA‑approved indication; all human use is off‑label or compounded.
Data last updated
Measured on 3 of 6 axes
Evidence shape
PE 22-28 currently lacks any published human clinical evidence or registered trials. Because no data exists to support its use for any specific indication, the peptide remains entirely unstudied in human populations. This absence of research means there is no established safety profile, effective dosage, or verified therapeutic outcome for the compound.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How PE 22-28 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Community users typically report 300 mcg, with doses ranging from 200 mcg to 800 mcg; one source notes daily administration while others do not specify frequency, and no cycling pattern is described.